Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
Globe Newswire•01/10/2026•08:05 ET
0
Key Highlights
- ➤Harmony Biosciences (HRMY) will present Phase 3 HBS-301 trial information October 2–3, 2026
- ➤HBS-301 is being evaluated in ONSTRIDE-1 for narcolepsy
- ➤HBS-301 is being evaluated in ONSTRIDE-2 for idiopathic hypersomnia
- ➤HBS-301 is an investigational high-dose formulation with strengths up to 60 mg
PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia. This poster will be presented at the 17th European Narcolepsy Days, taking place October 2–3, 2026, in Bern, Switzerland.
Abstract Title :Phase 3, randomized, double-blind, placebo-controlled studies of HBS-301 for narcolepsy and idiopathic hypersomnia
Get started
Create a free account to read the full story.